Patent · US Active

Method of treatment of pain by administration of a CCL17 specific antibody

US9988445B2 · kind B2 · utility

0Cited by

1References

14Claims

0Family size

Assignee

The University of Melbourne · AU

Inventors

Andrew David Cook · Melbourne, AU
John Allan Hamilton · Melbourne, AU
Adrian Achuthan · Melbourne, AU
Derek Lacey · Melbourne, AU

Key dates

Filing date	Sep 2, 2014
Grant date	Jun 5, 2018
Priority date	—
Expiry date	Oct 15, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A protocol for pain management includes a pharmaceutical composition and its use in ameliorating the sensation of pain. The protocol includes the use of a CCL17 signaling antagonist alone or in combination with another analgesic compound to treat pain associated with inflammatory conditions. The CCL17 signaling antagonist includes an antibody or antigen-binding derivative thereof which binds to CCL17 or its receptor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.